Form 8-K - Current report:
SEC Accession No. 0001193125-25-129448
Filing Date
2025-05-28
Accepted
2025-05-28 16:00:42
Documents
13
Period of Report
2025-05-27
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d944707d8k.htm   iXBRL 8-K 28398
2 EX-3.1 d944707dex31.htm EX-3.1 8457
  Complete submission text file 0001193125-25-129448.txt   150854

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lyel-20250527.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20250527_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20250527_pre.xml EX-101.PRE 10809
15 EXTRACTED XBRL INSTANCE DOCUMENT d944707d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 25995293
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)